Interstitial Lung Diseases Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Interstitial Lung Diseases Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Interstitial Lung Diseases Research. Learn more about our innovative pipeline today! @ Interstitial Lung Diseases Pipeline Outlook [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Interstitial Lung Diseases Pipeline Report

* In October 2024:- Boehringer Ingelheim- This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue treatment throughout the study.
* In October 2024:- Children's Hospital Medical Center, Cincinnati- This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric subjects greater than or equal to 50 kg and adult subjects (cohort 1), with an additional cohort (#2) of pediatric subjects
* In October 2024:- United Therapeutics- Study RIN-PF-303 is a multinational, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with IPF over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved.
* DelveInsight's Interstitial Lung Diseases pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Diseases treatment.
* The leading Interstitial Lung Diseases Companies such as Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
* Promising Interstitial Lung Diseases Therapies such as Dotarem, Belimumab, Nintedanib (Ofev Registered ), Anlotinib, BI 1015550, Abatacept, and others.

Stay informed about the cutting-edge advancements in Interstitial Lung Diseases Treatments. Download for updates and be a part of the revolution in cancer care @ Interstitial Lung Diseases Clinical Trials Assessment [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Interstitial Lung Diseases Emerging Drugs Profile

* DWN12088: Daewoong Pharmaceutical

DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body's ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein's sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.

* LYT-100: PureTech

LYT-100 is PureTech's most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.

* BMS-986278: Bristol-Myers Squibb

BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and -arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation

Learn more about Interstitial Lung Diseases Drugs opportunities in our groundbreaking Interstitial Lung Diseases Research and development projects @ Interstitial Lung Diseases Unmet Needs [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous

Interstitial Lung Diseases Products have been categorized under various Molecule types such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Interstitial Lung Diseases Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Interstitial Lung Diseases Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Interstitial Lung Diseases Pipeline Report

* Coverage- Global
* Interstitial Lung Diseases Companies- Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
* Interstitial Lung Diseases Therapies- Dotarem, Belimumab, Nintedanib (Ofev Registered ), Anlotinib, BI 1015550, Abatacept, and others.
* Interstitial Lung Diseases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Interstitial Lung Diseases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Interstitial Lung Diseases Pipeline on our website @ Interstitial Lung Diseases Drugs and Companies [https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Interstitial Lung Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Interstitial Lung Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RO-0220912: Roche
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Daratumumab: Janssen Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* BGB 16673: BeiGene
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Interstitial Lung Disease Key Companies
* Interstitial Lung Disease Key Products
* Interstitial Lung Disease- Unmet Needs
* Interstitial Lung Disease- Market Drivers and Barriers
* Interstitial Lung Disease- Future Perspectives and Conclusion
* Interstitial Lung Disease Analyst Views
* Interstitial Lung Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=interstitial-lung-diseases-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.